Loading…
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study
Purpose No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and...
Saved in:
| Published in: | Journal of cancer research and clinical oncology 2013-09, Vol.139 (9), p.1569-1577 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3 |
| container_end_page | 1577 |
| container_issue | 9 |
| container_start_page | 1569 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 139 |
| creator | Minicozzi, Pamela Bella, Francesca Toss, Angela Giacomin, Adriano Fusco, Mario Zarcone, Maurizio Tumino, Rosario Falcini, Fabio Cesaraccio, Rosaria Candela, Giuseppa La Rosa, Francesco Federico, Massimo Sant, Milena |
| description | Purpose
No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient.
Methods
Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003–2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated.
Results
Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women |
| doi_str_mv | 10.1007/s00432-013-1478-1 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1424323276</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3058142451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3</originalsourceid><addsrcrecordid>eNp1kUtr3TAQhUVpaG7S_oBuiqAUslGjkWRL7i6EviAQCO1ayNKoOPjarmRfuP--cn37oNCVGJ3vzAxzCHkJ_C1wrq8z50oKxkEyUNoweEJ2sP6AlNVTsuOggVUC6nNykfMjL3WlxTNyLqRphOLNjuAD9m7uDkjdEGjoMrqMLCZEmpd06A6up3FMtE1FmKl3g8dEu4Gmn75xoPNYyHY-TviOOjqN07IJrC2dAs3zEo7PyVl0fcYXp_eSfP3w_svtJ3Z3__Hz7c0d84qLmVVBt02MRtRotIa2amQwFXAXhQEBAgN6VMLpGEyNzkclGunQASjQ0Ud5Sa62vlMavy-YZ7vvsse-dwOOS7agRDmPFLou6Ot_0MdxSUPZbqWMBiGkKhRslE9jzgmjnVK3d-logds1A7tlYEsGds3AQvG8OnVe2j2G345fRy_AmxPgsnd9TOWoXf7Dle1EbdbhYuNykYZvmP5a8b_TfwDcvp6j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428712234</pqid></control><display><type>article</type><title>Relative and disease-free survival for breast cancer in relation to subtype: a population-based study</title><source>Springer Nature</source><creator>Minicozzi, Pamela ; Bella, Francesca ; Toss, Angela ; Giacomin, Adriano ; Fusco, Mario ; Zarcone, Maurizio ; Tumino, Rosario ; Falcini, Fabio ; Cesaraccio, Rosaria ; Candela, Giuseppa ; La Rosa, Francesco ; Federico, Massimo ; Sant, Milena</creator><creatorcontrib>Minicozzi, Pamela ; Bella, Francesca ; Toss, Angela ; Giacomin, Adriano ; Fusco, Mario ; Zarcone, Maurizio ; Tumino, Rosario ; Falcini, Fabio ; Cesaraccio, Rosaria ; Candela, Giuseppa ; La Rosa, Francesco ; Federico, Massimo ; Sant, Milena</creatorcontrib><description>Purpose
No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient.
Methods
Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003–2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated.
Results
Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women <40 years.
Conclusions
Our population-based findings confirm that subtype is an independent prognostic factor for BC. Triple-negative and HER2-enriched subtypes would benefit from the development and wide application, respectively, of targeted treatments, which would also improve survival for younger patients.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-013-1478-1</identifier><identifier>PMID: 23892409</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - classification ; Breast Neoplasms - epidemiology ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer Research ; Carcinoma, Ductal, Breast - epidemiology ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Ductal, Breast - secondary ; Carcinoma, Lobular - epidemiology ; Carcinoma, Lobular - mortality ; Carcinoma, Lobular - secondary ; Epidermal growth factor ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Hematology ; Hormones ; Humans ; Immunoenzyme Techniques ; Internal Medicine ; Italy - epidemiology ; Lymph Nodes - pathology ; Mammary gland diseases ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Recurrence, Local - classification ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Oncology ; Original Paper ; Pharmacology. Drug treatments ; Prognosis ; Proteins ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Risk factors ; Survival Rate ; Tumors ; Young Adult</subject><ispartof>Journal of cancer research and clinical oncology, 2013-09, Vol.139 (9), p.1569-1577</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3</citedby><cites>FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27632684$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23892409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minicozzi, Pamela</creatorcontrib><creatorcontrib>Bella, Francesca</creatorcontrib><creatorcontrib>Toss, Angela</creatorcontrib><creatorcontrib>Giacomin, Adriano</creatorcontrib><creatorcontrib>Fusco, Mario</creatorcontrib><creatorcontrib>Zarcone, Maurizio</creatorcontrib><creatorcontrib>Tumino, Rosario</creatorcontrib><creatorcontrib>Falcini, Fabio</creatorcontrib><creatorcontrib>Cesaraccio, Rosaria</creatorcontrib><creatorcontrib>Candela, Giuseppa</creatorcontrib><creatorcontrib>La Rosa, Francesco</creatorcontrib><creatorcontrib>Federico, Massimo</creatorcontrib><creatorcontrib>Sant, Milena</creatorcontrib><title>Relative and disease-free survival for breast cancer in relation to subtype: a population-based study</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient.
Methods
Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003–2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated.
Results
Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women <40 years.
Conclusions
Our population-based findings confirm that subtype is an independent prognostic factor for BC. Triple-negative and HER2-enriched subtypes would benefit from the development and wide application, respectively, of targeted treatments, which would also improve survival for younger patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - classification</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Carcinoma, Ductal, Breast - epidemiology</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Ductal, Breast - secondary</subject><subject>Carcinoma, Lobular - epidemiology</subject><subject>Carcinoma, Lobular - mortality</subject><subject>Carcinoma, Lobular - secondary</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematology</subject><subject>Hormones</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Internal Medicine</subject><subject>Italy - epidemiology</subject><subject>Lymph Nodes - pathology</subject><subject>Mammary gland diseases</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Recurrence, Local - classification</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Risk factors</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kUtr3TAQhUVpaG7S_oBuiqAUslGjkWRL7i6EviAQCO1ayNKoOPjarmRfuP--cn37oNCVGJ3vzAxzCHkJ_C1wrq8z50oKxkEyUNoweEJ2sP6AlNVTsuOggVUC6nNykfMjL3WlxTNyLqRphOLNjuAD9m7uDkjdEGjoMrqMLCZEmpd06A6up3FMtE1FmKl3g8dEu4Gmn75xoPNYyHY-TviOOjqN07IJrC2dAs3zEo7PyVl0fcYXp_eSfP3w_svtJ3Z3__Hz7c0d84qLmVVBt02MRtRotIa2amQwFXAXhQEBAgN6VMLpGEyNzkclGunQASjQ0Ud5Sa62vlMavy-YZ7vvsse-dwOOS7agRDmPFLou6Ot_0MdxSUPZbqWMBiGkKhRslE9jzgmjnVK3d-logds1A7tlYEsGds3AQvG8OnVe2j2G345fRy_AmxPgsnd9TOWoXf7Dle1EbdbhYuNykYZvmP5a8b_TfwDcvp6j</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Minicozzi, Pamela</creator><creator>Bella, Francesca</creator><creator>Toss, Angela</creator><creator>Giacomin, Adriano</creator><creator>Fusco, Mario</creator><creator>Zarcone, Maurizio</creator><creator>Tumino, Rosario</creator><creator>Falcini, Fabio</creator><creator>Cesaraccio, Rosaria</creator><creator>Candela, Giuseppa</creator><creator>La Rosa, Francesco</creator><creator>Federico, Massimo</creator><creator>Sant, Milena</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130901</creationdate><title>Relative and disease-free survival for breast cancer in relation to subtype: a population-based study</title><author>Minicozzi, Pamela ; Bella, Francesca ; Toss, Angela ; Giacomin, Adriano ; Fusco, Mario ; Zarcone, Maurizio ; Tumino, Rosario ; Falcini, Fabio ; Cesaraccio, Rosaria ; Candela, Giuseppa ; La Rosa, Francesco ; Federico, Massimo ; Sant, Milena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - classification</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Carcinoma, Ductal, Breast - epidemiology</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Ductal, Breast - secondary</topic><topic>Carcinoma, Lobular - epidemiology</topic><topic>Carcinoma, Lobular - mortality</topic><topic>Carcinoma, Lobular - secondary</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematology</topic><topic>Hormones</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Internal Medicine</topic><topic>Italy - epidemiology</topic><topic>Lymph Nodes - pathology</topic><topic>Mammary gland diseases</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Recurrence, Local - classification</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Risk factors</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minicozzi, Pamela</creatorcontrib><creatorcontrib>Bella, Francesca</creatorcontrib><creatorcontrib>Toss, Angela</creatorcontrib><creatorcontrib>Giacomin, Adriano</creatorcontrib><creatorcontrib>Fusco, Mario</creatorcontrib><creatorcontrib>Zarcone, Maurizio</creatorcontrib><creatorcontrib>Tumino, Rosario</creatorcontrib><creatorcontrib>Falcini, Fabio</creatorcontrib><creatorcontrib>Cesaraccio, Rosaria</creatorcontrib><creatorcontrib>Candela, Giuseppa</creatorcontrib><creatorcontrib>La Rosa, Francesco</creatorcontrib><creatorcontrib>Federico, Massimo</creatorcontrib><creatorcontrib>Sant, Milena</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minicozzi, Pamela</au><au>Bella, Francesca</au><au>Toss, Angela</au><au>Giacomin, Adriano</au><au>Fusco, Mario</au><au>Zarcone, Maurizio</au><au>Tumino, Rosario</au><au>Falcini, Fabio</au><au>Cesaraccio, Rosaria</au><au>Candela, Giuseppa</au><au>La Rosa, Francesco</au><au>Federico, Massimo</au><au>Sant, Milena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relative and disease-free survival for breast cancer in relation to subtype: a population-based study</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>139</volume><issue>9</issue><spage>1569</spage><epage>1577</epage><pages>1569-1577</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose
No population-based study has investigated breast cancer (BC) subtypes defined by including Ki67. The aim of this study was to evaluate the relative proportions of immunohistochemical subtypes and differences in relative and disease-free survival between subtypes, in relation to patient and other cancer characteristics in Italian BC patient.
Methods
Information on estrogen, progesterone, human epidermal growth factor (HER2), Ki67, and relapses was obtained for 3,381 cases, sampled randomly and anonymously from cases diagnosed in 2003–2005 in nine Italian cancer registries. Relative excess risks (RERs) of death and risks of relapse 5 years after diagnosis were estimated.
Results
Luminal A cancers were 42 % of the total, luminal B 27 %, luminal-HER2 14 %, triple-negative 11 %, and HER2-enriched 7 %. For non-metastatic (3,302) cases, 4 and 7 % developed locoregional and distant metastases, respectively. RERs of death and risks of relapse were significantly greater for all cancer subtypes than luminal A, particularly for triple-negative and HER2-enriched cancers, which were more frequent in women <40 years.
Conclusions
Our population-based findings confirm that subtype is an independent prognostic factor for BC. Triple-negative and HER2-enriched subtypes would benefit from the development and wide application, respectively, of targeted treatments, which would also improve survival for younger patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>23892409</pmid><doi>10.1007/s00432-013-1478-1</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2013-09, Vol.139 (9), p.1569-1577 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1424323276 |
| source | Springer Nature |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Breast cancer Breast Neoplasms - classification Breast Neoplasms - epidemiology Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Research Carcinoma, Ductal, Breast - epidemiology Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - secondary Carcinoma, Lobular - epidemiology Carcinoma, Lobular - mortality Carcinoma, Lobular - secondary Epidermal growth factor Female Follow-Up Studies Gynecology. Andrology. Obstetrics Hematology Hormones Humans Immunoenzyme Techniques Internal Medicine Italy - epidemiology Lymph Nodes - pathology Mammary gland diseases Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Recurrence, Local - classification Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Oncology Original Paper Pharmacology. Drug treatments Prognosis Proteins Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Risk factors Survival Rate Tumors Young Adult |
| title | Relative and disease-free survival for breast cancer in relation to subtype: a population-based study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relative%20and%20disease-free%20survival%20for%20breast%20cancer%20in%20relation%20to%20subtype:%20a%20population-based%20study&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Minicozzi,%20Pamela&rft.date=2013-09-01&rft.volume=139&rft.issue=9&rft.spage=1569&rft.epage=1577&rft.pages=1569-1577&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-013-1478-1&rft_dat=%3Cproquest_cross%3E3058142451%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c402t-5d7b9ff826e8771b593d8510af281212edece42a7fd86eacf4293aea11417fcf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1428712234&rft_id=info:pmid/23892409&rfr_iscdi=true |